These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 10037394)

  • 21. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
    Park JI; Lee MG; Cho K; Park BJ; Chae KS; Byun DS; Ryu BK; Park YK; Chi SG
    Oncogene; 2003 Jul; 22(28):4314-32. PubMed ID: 12853969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
    Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
    Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
    Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
    Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
    Ripley D; Tang XM; Ma C; Chegini N
    Gynecol Oncol; 2001 May; 81(2):301-9. PubMed ID: 11330966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Makarov DV; Sanderson H; Partin AW; Epstein JI
    J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
    Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
    J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
    Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
    J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.
    Sung MT; Lin H; Koch MO; Davidson DD; Cheng L
    Am J Surg Pathol; 2007 Feb; 31(2):311-8. PubMed ID: 17255778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes.
    Olszewski WL; Pazdur J; Kubasiewicz E; Zaleska M; Cooke CJ; Miller NE
    Arthritis Rheum; 2001 Mar; 44(3):541-9. PubMed ID: 11263768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
    Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
    Freedland SJ; Mangold LA; Epstein JI; Partin AW
    Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
    Noguchi M; Stamey TA; Neal JE; Yemoto CE
    J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.